What Is PT-141 Injection? Bremelanotide Benefits, Risks, and FDA Status
PT-141 is the research name for bremelanotide, a melanocortin receptor agonist. FDA-approved bremelanotide (Vyleesi) is a prescription autoinjector for HSDD in premenopausal women. Compounded PT-141 injection is not FDA-approved and is not automatically the same product, dose, or device.
Written for Dominia Health education · Medically reviewed by Ariel Bowerman, BSN, R.N. · Last reviewed September 9, 2026
Tampa, FL – September 9, 2026 – PT-141 is the research name for bremelanotide, a melanocortin receptor agonist. FDA-approved bremelanotide injection (Vyleesi) is a prescription autoinjector indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 injection is not FDA-approved and is not automatically the same product, dose, or device. Research-use-only PT-141 sold for human use is not recommended.
What Is It?
HSDD means low sexual desire that causes personal distress and is not explained primarily by another medical condition, relationship problem, or medication. Bremelanotide is used on an as-needed basis — not daily — in the FDA-approved formulation. PT-141 originated as a related melanocortin peptide in research settings; the approved medicine (Vyleesi) is a specific formulation and delivery device, not a generic equivalent of every product marketed under the PT-141 name.
How Does It Work?
Bremelanotide acts on melanocortin receptors in the central nervous system involved in regulating sexual desire. Unlike many treatments for sexual dysfunction, it is not a blood-flow drug. A plausible brain mechanism is not proof that a compounded vial or gray-market preparation will match the approved autoinjector in effect, safety, or consistency.
What Does the Evidence Show?
| Bucket | What it covers |
|---|---|
| Established | Two identical 24-week randomized trials of FDA-approved bremelanotide in 1,247 premenopausal women with acquired, generalized HSDD. |
| Emerging | Off-label use and compounded injections in other populations. Reports exist; large equivalent trials generally do not. |
| Unknown | Whether a given compounded PT-141 injection matches approved strength, sterility, or clinical effect. |
The FDA label states Vyleesi is indicated for premenopausal women with acquired, generalized HSDD and is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance.
What We Know
- An FDA-approved, as-needed subcutaneous product exists for a narrow, defined female indication.
- Nausea is common and can be intense. Blood pressure can rise temporarily after a dose.
- Focal darkening of the skin, gums, or breasts can occur and may not fully resolve.
What We Don't Know
- Whether compounded PT-141 from a particular pharmacy is equivalent to Vyleesi in strength, sterility, or effect.
- How well it works for male low desire or erectile concerns in the same way the labeled trials measured female HSDD.
- Long-term effects of frequent unapproved or research-only use.
What this page does not establish: That "PT-141 shots from the internet" are the FDA-approved drug.
Potential Benefits
- Established, modest benefit on desire and related distress in the labeled population using the approved product.
- On-demand use rather than a daily pill, for people who qualify and tolerate it.
Risks and Side Effects
Common: nausea, flushing, injection-site reactions, headache.
Important: temporary increase in blood pressure and decrease in heart rate after dosing; darkening of skin, gums, or breasts; nausea that can be intense.
Per labeling, avoid use in uncontrolled hypertension or known cardiovascular disease.
Contact a clinician for severe nausea, unusual skin darkening, or blood-pressure symptoms. Seek urgent care for chest pain, trouble breathing, or signs of a severe allergic reaction.
Do not estimate a home dose in "units." Use only the product and instructions provided by the prescribing clinician and dispensing pharmacy. Concentrations of compounded injections can vary significantly.
FDA Status (as of September 2026)
Bremelanotide injection is FDA-approved as Vyleesi for one defined indication. A compounded PT-141 injection is not reviewed by the FDA for safety, effectiveness, or quality before marketing in the same way as the approved autoinjector. Compounding eligibility for bulk peptides can change; a committee vote is advisory until FDA completes rulemaking. Research-use-only vials are not approved medicines for human use.
Comparing the Products
| FDA-approved bremelanotide (Vyleesi) | Compounded PT-141 injection | Research-use-only PT-141 | |
|---|---|---|---|
| FDA premarket review | Yes, for labeled HSDD use | No | No |
| Typical presentation | Single-dose autoinjector | Often multi-dose vials; strengths vary | Unregulated research listing |
| Studied population | Premenopausal women with HSDD | Not established as equivalent | Not for human use |
| Approved for men / performance | No | Not FDA-approved | Not recommended |
Who May or May Not Be Appropriate
A licensed clinician may consider the FDA-approved product for premenopausal women who meet HSDD criteria after other contributing causes have been evaluated. People with uncontrolled high blood pressure or cardiovascular disease, and anyone offered an unlabeled research vial, require a different clinical conversation. This article cannot determine whether any therapy is appropriate for you.
From Our Founders
"I read the Vyleesi label next to the PT-141 marketing pages. The approved autoinjector for a defined women's diagnosis is not the same offer as a research vial labeled 'not for human use.' Talk to your provider about which product, if any, is actually being prescribed."
— Ana Argote, BSN, R.N. (ARNP student)
Frequently Asked Questions
What is PT-141 injection? A subcutaneous injection of bremelanotide. The FDA-approved version is a specific autoinjector (Vyleesi). Compounded and research versions are different preparations and are not the same product.
Is PT-141 FDA approved? The molecule is approved as Vyleesi for HSDD in premenopausal women. A compounded PT-141 injection is not that approved product.
Does it work? Clinical trials showed a statistically significant but modest effect in the labeled population. It is not a guarantee of improved sexual desire.
Is it safe? It has a described risk profile, including nausea and short-term blood-pressure changes. "Safe for everyone" is not an accurate characterization.
Can men use it? The approved indication does not include men. Off-label prescribing is a clinician decision; it is not the same as FDA approval for that use.
Is a research peptide the same thing? No. Dominia Health does not recommend research-use-only products for human use. Those products are not reviewed as medicines for people.
Bottom Line
FDA-approved bremelanotide injection has established, limited trial evidence for one specific women's diagnosis. Compounded PT-141 injection is not FDA-approved and should not be described as the same product. Research-use-only PT-141 is not for human use.
So what? Ask which exact product you would receive — approved autoinjector, compounded vial, or a website "research" bottle — before assuming the trial results apply to your situation.
Have questions about whether a prescribed option may be appropriate for you? Talk with a licensed healthcare provider. To learn more or request a consultation, visit Dominia Health.
Sources: FDA Vyleesi prescribing information
Written by: Dominia Health education
Medically reviewed by: Ariel Bowerman, BSN, R.N.
Published / last updated: September 9, 2026
Explore Topics
Written by
Dominia Health
Content creator and writer sharing insights and stories.
